And finally, dilution remains the thorn in the side of any marijuana stock investor -- especially shareholders in Aurora Cannabis. The company's latest share count (in Canada) showed 564.8 million shares outstanding, up almost 75 million shares from the sequential second quarter. Further, it had more than 26 million options, almost 18 million convertible debentures, and over 8 million warrants outstanding as of the end of May 7, 2018. In other words, this dilution is going to continue to get worse, making it tougher for the company to turn a meaningful per-share profit, as well as diluting the value of each existing share.
While a lot has gone right for Aurora, its lack of near-term profitability and ongoing dilution make it a risky bet for investors.
Euch ist schon klar das der Deal mit MedReleaf nochmal 400 millionen ungefähr Aktienanteile bringt oder? 490m+400m = 890m an outstanding Aktienanteile.
|